Project Grant R44CA216539

This Project Grant award, valued at $597,766.00, is funded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The University of Pennsylvania will develop novel methods to image two PET tracers with different molecular targets back-to-back in a single imaging session using a long-axial field-of-view PET scanner, the PennPET Explorer. The key objectives are: Develop protocols to image fluoroglutamine, a research radiotracer of...

This federal Project Grant award of $399,829, awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports research to validate the use of positron emission tomography (PET) imaging to quantitatively measure the levels of the sphingosine-1-phosphate receptor 1 (S1PR1) in gastric tumors. The goal is to use this S1PR1-targeted PET imaging approach to predict and monitor the response of gastric tumors to antibody-drug conjugate...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $799,962 to Tripill Biotechnology, Corp. to develop radiolabeled PSMA agents with low salivary gland uptake for improved prostate cancer imaging and therapy. The key products and services to be delivered include: Constructing PSMA derivative compounds, such as NOTA-UNC-PSMA2, that can selectively reduce salivary gland uptake while maintaining high tumor uptake in prostate...

The National Cancer Institute (NCI) awarded a 5-year, $678,515 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to The University of Texas MD Anderson Cancer Center to evaluate the use of 18F-FSPG PET imaging and liquid biopsy (circulating tumor DNA) to predict response and detect recurrence in hepatocellular carcinoma (liver cancer) patients treated with yttrium-90 radioembolization therapy. The project aims to determine if 18F-FSPG PET can identify treatment-resistant...

This Project Grant award, valued at $497,870 and provided by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), aims to develop a novel genetically-encoded molecular imaging approach for tracking genome-edited immune cells in vivo. The project will leverage bacterial metallophores as contrast agents to non-invasively monitor the distribution, turnover, and survival of these engineered cells using positron emission tomography (PET) imaging. The first phase will...

This federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to create a new surgical probe prototype for laparoscopic prostate cancer resection procedures. The $161,000 award will fund the development and testing of a probe specifically designed for use with Positron Emission Tomography (PET) radiotracers, which can better...

The Project Grant award R01CA287491, totaling $720,416, was provided by the National Cancer Institute (NCI) under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394). The award aims to develop a novel "theranostic" (therapeutic and diagnostic) approach using chimeric antigen receptor (CAR) T-cell therapy for the treatment of neuroendocrine prostate cancer (NEPC). The key products and services to be delivered include: Evaluating the therapeutic efficacy of...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $349,808 to Oncurie Inc. to continue development of a novel targeted radiopharmaceutical for imaging and potential therapy of ovarian cancer. The compound leverages the folate receptor overexpression in ovarian tumors to enable precision imaging, with future plans to incorporate cytotoxic radionuclides for targeted therapy. During the Phase I award period from Sep 2024...

This federal Project Grant award of $644,622 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to enhance radioligand therapy for prostate cancer through the development of biomarker and dosimetry-guided personalized treatment approaches. The key objectives are to: 1) develop a novel method for bone marrow dosimetry using macro/micro Monte Carlo modeling, 2) build predictive models to estimate absorbed radiation doses from pre-therapy PET...

The National Cancer Institute (CFDA 93.394 Cancer Detection and Diagnosis Research) awarded a $666,670 Project Grant to The Trustees of the University of Pennsylvania, effective January 15, 2025 through December 31, 2028. The goal of this project is to i) develop methods and protocols to obtain high-quality dynamic information from both PET and CT modalities, and ii) use dynamic spectral CT for PET kinetic modeling to reduce overall scan time to match existing clinical PET protocols (~20...